Key Drivers
- Margin Power
- Cash Strength
- Rich Valuation
AIAI Summary
NBIX has evolved from an INGREZZA-only story into a higher-quality, multi-engine growth platform with strong cash generation and margins, but at ~29x earnings the stock now depends on flawless execution of CRENESSITY and VYKAT XR while maintaining INGREZZA momentum, making concentration and integration risk the key swing factors from here.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Power
- •Cash Strength
- •Rich Valuation
NBIX remains financially strong, with near-100% gross margins, solid earnings and cash flow, and a resilient balance sheet, but heavy operating spend and a rich valuation limit upside.
Price Behavior
Key Price Behavior Insights:
- •Breakout hold
- •Higher lows
- •Pullback risk
NBIX looks constructive after breaking above the $167-$170 zone and reaching a new short-term high at $174.26 over the last month, but the quick run from $164.18 leaves it vulnerable to a pullback if support fails.
Quick move from $164.18 on 2026-06-25 to $174.26 on 2026-07-02 signals short-term volatility risk
Sentiment & News
Key News Insights:
- •Revenue growth
- •Clinical expansion
- •Analyst support
Neurocrine Biosciences shows strong momentum from rising revenue, supportive analyst sentiment, and ongoing clinical and pipeline progress across Ingrezza, Crenessity, and crinecerfont.
The news flow is constructive for NBIX, reinforcing both near-term commercial strength and longer-term pipeline confidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings